Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 28;39(7):797–806. doi: 10.1200/JCO.20.02220

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

FIG 2. — Relationship between the maximum tumor volume change from baseline and the AUC_0-12h estimate in steady state (R² = 0.22; P = .052). The predicted exposure of mirdametinib at tumor size readout (as measured by AUC_0-12h) was compared with maximum tumor volume change from baseline in individual patients using linear regression analysis. Blue triangles represent patients who did not achieve a partial response (PR). Red circles are those patients who did achieve a PR; one patient who achieved a PR did not have pharmacokinetics performed. Filled in shapes represent patients who had a dose reduction, only one of whom achieved a PR (although the dose reduction was after the PR was achieved). The patient near the very top of the graph had a small plexiform neurofibroma that significantly progressed in the first eight courses. AUC_0-12h, area under the concentration-time curve from time 0 to 12 hours.